10 months ago
APLT
AnalystsBrian SkorneyBrian Skorney's Stock Forecasts
AnalystsBrian Skorney
Analyst Ranking
Top 37%
#1834 out of 5020 analysts
Average Return
+0.65%
Win Rate
45%37 out of 82
Risk vs Reward
Poor
Good
Brian Skorney's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Applied Therapeutics IncAPLT | +220.68% | $1.34 | $4.31 | 2023-04-25 - 2024-04-24 | Buy |
Crinetics Pharmaceuticals IncCRNX | +195.52% | $15.84 | $46.81 | 2023-03-29 - 2024-03-28 | Buy |
Albireo Pharma IncALBO | +144.19% | $18.08 | $44.15 | 2022-08-16 - 2023-03-02 | Buy |
Intercept Pharmaceuticals IncICPT | +99.37% | $9.53 | $19.00 | 2023-05-22 - 2023-11-07 | Buy |
Albireo Pharma IncALBO | +98.61% | $22.23 | $44.15 | 2022-10-12 - 2023-03-02 | Buy |
Brian Skorney Analyst Color
Get additional color on Brian Skorney's coverage of popular stocks
10 months ago
SRPT
Brian Skorney's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Biohaven LtdBHVN | 4 | Buy | $52.00 | +253.74% | Maintains | a month ago |
Sarepta Therapeutics IncSRPT | 7 | Buy | $35.00 | +105.28% | Maintains | 2 months ago |
Soleno Therapeutics IncSLNO | 5 | Buy | $121.00 | +137.35% | Maintains | 2 months ago |
Dyne Therapeutics IncDYN | 2 | Buy | $32.00 | +143.35% | Maintains | 3 months ago |
Biogen IncBIIB | 9 | Buy | $255.00 | +76.02% | Maintains | 5 months ago |
Regeneron Pharmaceuticals IncREGN | 11 | Hold | $587.00 | +0.26% | Maintains | 5 months ago |
Mirum Pharmaceuticals IncMIRM | 5 | Buy | $55.00 | -24.80% | Maintains | 7 months ago |
Gilead Sciences IncGILD | 3 | Hold | $100.00 | -10.92% | Maintains | 7 months ago |
Benitec Biopharma IncBNTC | 1 | Buy | $30.00 | +118.98% | Initiates Coverage On | 9 months ago |
Applied Therapeutics IncAPLT | 3 | Buy | $5.00 | +1,116.55% | Maintains | 10 months ago |
Enanta Pharmaceuticals IncENTA | 4 | Buy | $20.00 | +165.25% | Maintains | 10 months ago |
Alumis IncALMS | 1 | Buy | $25.00 | +505.33% | Initiates Coverage On | a year ago |
Alto Neuroscience IncANRO | 2 | Buy | $10.00 | +161.78% | Maintains | a year ago |
Amgen IncAMGN | 3 | Sell | $215.00 | -21.74% | Reiterates | a year ago |
Neurocrine Biosciences IncNBIX | 4 | Buy | $180.00 | N/A | Maintains | a year ago |
Lexeo Therapeutics IncLXEO | 1 | Buy | $28.00 | N/A | Initiates Coverage On | a year ago |
Crinetics Pharmaceuticals IncCRNX | 4 | Buy | $62.00 | N/A | Maintains | a year ago |
Marinus Pharmaceuticals IncMRNS | 4 | Hold | $2.00 | N/A | Downgrades | a year ago |
Regenxbio IncRGNX | 3 | Buy | $39.00 | N/A | Maintains | 2 years ago |
Onkure Therapeutics IncOKUR | 2 | Hold | $30.00 | N/A | Downgrades | 2 years ago |
Xenon Pharmaceuticals IncXENE | 1 | Buy | $63.00 | N/A | Initiates Coverage On | 2 years ago |
Reata Pharmaceuticals IncRETA | 6 | Buy | $173.00 | N/A | Maintains | 2 years ago |
Eiger Biopharmaceuticals IncEIGRQ | 1 | Buy | $150.00 | N/A | Maintains | 2 years ago |
Intercept Pharmaceuticals IncICPT | 3 | Buy | $18.00 | N/A | Maintains | 2 years ago |
Vertex Pharmaceuticals IncVRTX | 13 | Hold | $325.00 | N/A | Maintains | 2 years ago |
Myovant Sciences LtdMYOV | 1 | Hold | $27.00 | N/A | Downgrades | 3 years ago |
Albireo Pharma IncALBO | 4 | Buy | $55.00 | N/A | Maintains | 3 years ago |
Immunovant IncIMVT | 1 | Hold | $10.00 | N/A | Downgrades | 4 years ago |
Vistagen Therapeutics IncVTGN | 1 | Buy | $270.00 | N/A | Initiates Coverage On | 4 years ago |
Voyager Therapeutics IncVYGR | 1 | Hold | $6.00 | N/A | Downgrades | 5 years ago |
Principia Biopharma IncPRNB | 1 | Buy | $78.00 | N/A | Maintains | 5 years ago |
Celgene CorpCELG | 2 | Buy | $92.00 | N/A | Upgrades | 7 years ago |
Curis IncCRIS | 3 | Buy | $300.00 | N/A | Maintains | 7 years ago |
Ablynx NvABLX | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Beone Medicines LtdONC | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Cempra IncCEMP | 1 | Hold | N/A | N/A | Upgrades | 8 years ago |
Achillion Pharmaceuticals IncACHN | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.